Therapeutically, we show that pharmacologic inhibition of ECM organization, administered at the point of minimal tumor burden, restores CD8+ T cell infiltration and delays the emergence of BRAF/MEKi resistance in a CD8+ T cell–dependent manner. The gene discussed is BRAF; the disease is neoplasm.